Crispr Theraptc (NASDAQ:CRSP) Insider Tyler Dylan-Hyde Sells 15,000 Shares
Crispr Theraptc (NASDAQ:CRSP) insider Tyler Dylan-Hyde sold 15,000 shares of the stock in a transaction dated Tuesday, August 8th. The shares were sold at an average price of $18.57, for a total transaction of $278,550.00. Following the completion of the sale, the insider now owns 167,727 shares of the company’s stock, valued at approximately $3,114,690.39. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink.
Crispr Theraptc (NASDAQ CRSP) traded up 1.30% during midday trading on Tuesday, reaching $18.74. 146,378 shares of the company’s stock traded hands. The firm’s 50-day moving average is $16.62 and its 200 day moving average is $17.58. The firm’s market cap is $749.54 million. Crispr Theraptc has a 52-week low of $11.63 and a 52-week high of $25.00.
Crispr Theraptc (NASDAQ:CRSP) last issued its earnings results on Thursday, May 11th. The company reported ($0.54) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.60) by $0.06. The firm had revenue of $2.70 million during the quarter. Equities research analysts expect that Crispr Theraptc will post ($2.46) earnings per share for the current fiscal year.
TRADEMARK VIOLATION WARNING: This article was originally published by American Banking News and is the property of of American Banking News. If you are viewing this article on another publication, it was illegally copied and reposted in violation of United States and international copyright & trademark laws. The original version of this article can be read at https://www.americanbankingnews.com/2017/08/08/crispr-theraptc-nasdaqcrsp-insider-tyler-dylan-hyde-sells-15000-shares.html.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in CRSP. Credit Suisse AG bought a new position in Crispr Theraptc during the first quarter valued at $1,742,000. Paulson & CO. Inc. bought a new position in Crispr Theraptc during the first quarter valued at $1,099,000. Monashee Investment Management LLC boosted its position in Crispr Theraptc by 208.7% in the first quarter. Monashee Investment Management LLC now owns 22,186 shares of the company’s stock valued at $473,000 after buying an additional 15,000 shares during the last quarter. IHT Wealth Management LLC bought a new position in Crispr Theraptc during the first quarter valued at $110,000. Finally, Wellington Management Group LLP boosted its position in Crispr Theraptc by 0.4% in the first quarter. Wellington Management Group LLP now owns 747,450 shares of the company’s stock valued at $16,272,000 after buying an additional 3,070 shares during the last quarter. 24.08% of the stock is owned by hedge funds and other institutional investors.
Several equities research analysts have commented on the stock. Oppenheimer Holdings, Inc. reiterated a “market perform” rating on shares of Crispr Theraptc in a research note on Tuesday, July 18th. SunTrust Banks, Inc. assumed coverage on shares of Crispr Theraptc in a research note on Thursday, July 13th. They issued a “hold” rating and a $16.00 price objective for the company. Finally, Cann assumed coverage on shares of Crispr Theraptc in a research note on Monday, July 17th. They issued a “market perform” rating for the company. Four analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $21.92.
About Crispr Theraptc
Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell.
Receive News & Ratings for Crispr Theraptc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crispr Theraptc and related companies with MarketBeat.com's FREE daily email newsletter.